PT-141 (Bremelanotide) Dosage Guide: Reconstitution and Research Protocol
Practical guide to PT-141 vial reconstitution, injection volume tables, standard research dosing for sexual dysfunction research, and timing guidance.
Ready to calculate your exact injection volume?
Enter your vial size, concentration, and target dose to get precise volumes instantly.
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for sexual dysfunction in both male and female research subjects. It is an approved drug (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. This guide covers research vial reconstitution and dosing.
What Vials Typically Come In
PT-141 research vials are available as:
- 10 mg vials (most common)
- 5 mg vials
How to Reconstitute PT-141
Standard reconstitution for a 10 mg vial:
1. Swab rubber stopper with alcohol; allow to dry
2. Draw 2 mL bacteriostatic water
3. Inject water slowly down the inside vial wall
4. Swirl gently — do not shake
5. Allow 2 minutes for complete dissolution
Concentration examples:
- 10 mg + 1 mL BW → 10,000 mcg/mL
- 10 mg + 2 mL BW → 5000 mcg/mL
- 10 mg + 5 mL BW → 2000 mcg/mL
The 2000 mcg/mL dilution (10 mg in 5 mL) is popular for the 1–2 mg dose range as it provides more manageable injection volumes.
Standard Research Dosage Ranges
| Indication | Dose | Timing |
|---|---|---|
| Male sexual dysfunction | 1–2 mg | 30–60 min before |
| Female HSDD (clinical) | 1.75 mg | 45 min before |
| Lower sensitivity testing | 0.5–1 mg | 30–60 min before |
The approved clinical dose is 1.75 mg subcutaneous. Research protocols often explore the 1–2 mg range.
Injection Volume Table
Using a 2000 mcg/mL solution (10 mg in 5 mL BW):
| Target Dose | Volume to Inject |
|---|---|
| 0.5 mg (500 mcg) | 0.25 mL (25 units) |
| 1 mg (1000 mcg) | 0.50 mL (50 units) |
| 1.75 mg (1750 mcg) | 0.875 mL (~87.5 units) |
| 2 mg (2000 mcg) | 1.00 mL (100 units) |
Use the Dose Calculator to compute volumes for your specific vial concentration.
Timing and Cycle Length
- Timing: Administer 30–60 minutes before the relevant research observation period
- Frequency: As-needed dosing; typically not more than once per 24 hours
- Injection site: Subcutaneous to abdomen or thigh
- Cycle: PT-141 is used on an as-needed basis rather than a daily cycle
Side Effects to Monitor
Common in research: transient nausea (often mild), facial flushing, transient blood pressure elevation. Nausea typically resolves within 1–2 hours.
Storage
- Lyophilised vials: -20°C for long-term; 2–8°C short-term
- After reconstitution: 2–8°C; use within 28 days
Calculate Your Exact Injection Volume
Use our free dose calculator — enter any vial size and target dose to get the precise volume to draw up.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.